spacer
home > ebr > summer 2018 > calibrating expectations
PUBLICATIONS
European Biopharmaceutical Review

Calibrating Expectations

In Europe and the US, biosimilar drugs are gaining acceptance among physicians, payers, and patients in areas such as kidney disease, growth disorders, cancer, and auto-immune conditions. Progress has been slower in diabetes, but the pandemic nature and heavy cost burdens of the illness may fuel demand for biosimilars in the future. Examining the track record of follow-on biologics in other therapeutic areas can suggest constructive ways to envision the future for diabetes.

By many measures, the global epidemic in diabetes dwarfs other public health challenges. An estimated 60 million Europeans and 30 million Americans have diabetes today. In the US, about 1.5 million people are diagnosed with the disease each year. Many of them patients have transitioned from prediabetes, which affects 84 million Americans. The economic toll is also difficult to ignore.

Direct medical costs linked to diabetes come to about $237 billion a year in the US – more than for any other illness. Insulin and other anti-diabetic drugs, along with treatments for complications, make up 45% of total direct costs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rafal Kokolus brings to Syneos Health more than 10 years of combined pharma consulting and drug development/commercialisation experience. He has supported several major pharma and biotech companies in maximising the commercial value of pipeline and in-line assets and optimising marketing and brand strategy. Rafal earned an MBA from University of Western Ontario’s Richard Ivey School of Business, Canada, and a BSc in cell biology and genetics from the University of British Columbia, Canada, and a Graduate Diploma in business administration from Simon Fraser University, Canada.

Dr Doug Niven specialises in pricing and market access at Syneos Health where he has been for the last six years. Prior to this, Doug worked within PwC’s Healthcare Strategy practice. Doug holds a PhD in physics from the University of Birmingham, UK, and a BSc in economics and finance from the University of London, UK.

Rohit Sood leads the global commercial strategy and planning practice at Syneos Health Consulting. During his 12 years at Syneos, he has advised clients in the areas of portfolio planning, commercialisation and launch excellence, and corporate strategy. Rohit has worked with several clients helping them think through their biosimilar go-to-market strategy.
spacer
Rafal Kokolus
spacer
spacer
spacer
Dr Doug Niven
spacer
spacer
spacer
Rohit Sood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Why You Should Be Using Ultrasonic Cleaning

Natoli Engineering Company, Inc.

Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling. The Tableting Specification Manual (TSM) states, “An ultrasonic bath is ideal for cleaning tooling.” This high-tech cleaning process also saves time, reduces cost and is better for the environment.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement